Definitive multinational efficacy trials and pioneering ‘real-world’ evidence informing treatments and international strategy for managing chronic obstructive pulmonary disease (COPD)

Impact: Health and wellbeing

Narrative

Our translational research brought about a step change in the clinical management of COPD from simple inhaled therapies to more efficacious, safer novel combination inhaled therapies. Notably, Chiesi’s Trimbow triple inhaler, approved by the European Medicines Agency (EMA) and available in 19 European countries, has simplified treatment for COPD patients. Our research has informed Global Initiative for Chronic Obstructive Lung Disease (GOLD) international strategy and in 2019 was evidenced by the National Institute for Health and Care Excellence (NICE) in updating their COPD guidelines. The team initiated a paradigm shift for experimental medicine by evaluating ‘real-world’ effectiveness for the first time among primary care patients in a deprived population with high prevalence of smoking and co-morbid cardiovascular disease, a model that GlaxoSmithKline (GSK) now uses in trials in other diseases.
Impact date1 Jan 2016 → 31 Dec 2020
Category of impactHealth and wellbeing
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Lydia Becker Institute

Documents & Links

Related content